Comparative Pharmacology
Head-to-head clinical analysis: GLEOSTINE versus MELPHALAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GLEOSTINE versus MELPHALAN.
GLEOSTINE vs MELPHALAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
GLEOSTINE (lomustine) is a nitrosourea alkylating agent that crosslinks DNA and RNA, inhibiting DNA synthesis and repair. It is cell cycle phase-nonspecific.
Melphalan is an alkylating agent that forms interstrand crosslinks with DNA, inhibiting DNA replication and transcription, leading to cell death.
130 mg/m2 orally every 6 weeks as a single dose; alternatively, 75 mg/m2 orally every 3 weeks.
Melphalan 0.25 mg/kg/day orally for 4 consecutive days, repeated every 4-6 weeks; or 16 mg/m² intravenously over 15-20 minutes at 2-week intervals for 4 doses.
None Documented
None Documented
16-48 hours (terminal), with an active metabolite half-life of up to 5 days, requiring dose adjustment for renal impairment
Clinical Note
moderateMelphalan + Digoxin
"Melphalan may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateMelphalan + Digitoxin
"Melphalan may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateMelphalan + Deslanoside
"Melphalan may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateMelphalan + Acetyldigitoxin
"Melphalan may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal half-life: 1.5-2 hours (IV); prolonged in renal impairment (up to 3-4 hours).
Renal: 60% (as metabolites), Fecal: <5% (unchanged and metabolites), Biliary: minimal
Renal: 10-15% unchanged; hepatic metabolism (20-30%) with biliary excretion of metabolites; fecal: <5%.
Category C
Category D/X
Alkylating Agent
Alkylating Agent